Skip to main content
. Author manuscript; available in PMC: 2012 Jan 23.
Published in final edited form as: Clin Cancer Res. 2011 Jan 1;17(1):122–133. doi: 10.1158/1078-0432.CCR-10-0253

Figure 4. Characterization of PHA-665752-resistant (PR) GTL-16 tumor cells.

Figure 4

(A) GTL-16 and PR-GTL-16 tumor cells were treated with PHA-665752 as indicated. After 24 h, a BrdU cell proliferation assay was performed. (B) Cells were treated with 400 nM PHA-665752 for 24 h. Thereafter, flow cytometric analysis of the cell cycle distribution was performed. (C) RT-PCR analysis for 18s, MET and FGF-3 RNA of PR-GTL-16 as compared with parental GTL-16 tumor cells. CT = cycle threshold. * = in parental GTL-16 cells, no CT value could be determined, indicating that FGF-3 is not expressed in these cells. Data are depicted as mean ± SE.